A comprehensive meta-analysis by Deng et al. demonstrated that elevated pretreatment serum CEA levels correlate strongly with poor prognosis in gastric cancer patients, effectively doubling mortality risk [17]. The gene discussed is CEACAM5; the disease is gastric cancer.